Please read and agree to the terms and conditions of this site.
@xconomy.com 4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com 4 years ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com 4 years ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com 4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com 4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com 4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com 4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com 5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com 5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com 5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com 5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com 5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 5 years ago
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo
@xconomy.com 5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com 5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com 5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com 5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com 5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com 5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com 5 years ago
Pfizer, Merck Lead Strata Oncology’s $26M Series B Round
@xconomy.com 5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
@xconomy.com 6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?